Published in:
Open Access
01-12-2022 | Alzheimer's Disease | Perspective
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
Author:
Guojun Bu
Published in:
Molecular Neurodegeneration
|
Issue 1/2022
Login to get access
Excerpt
The
APOE gene is the strongest genetic risk factor for Alzheimer’s disease (AD) with the ε4 allele increasing the risk by 2-4 folds compared to the most common ε3 allele [
1]. The high prevalence of
APOE4 allele frequency (~ 14% in Caucasian non-demented versus ~ 38% in AD) and carrier frequency (~ 20-30% in Caucasian non-demented versus 50-70% in AD) in AD patients presents a strong rationale to target
APOE for AD prevention and therapy [
1]. More interestingly, carriers of the
APOE2 allele have a significantly reduced risk for AD [
2], further attracting interests to target this strong AD risk gene. …